Carol A. Tamminga
Member of the Scientific and Clinical Advisory BoardDr. Carol A. Tamminga, M.D is Member of Advisory Board of Terran Biosciences Inc. She served as Member of Scientific Advisory Board at Karuna Therapeutics, Inc. until March 18, 2024. She is the President of the American College of Neuropsychopharmacology. Dr. Tamminga is Chair of the Psychiatry Department, Professor of Psychiatry, Vice Chair for Clinical Research and Chief of Translational Neuroscience Research in Schizophrenia at the Graduate School of Biomedical Sciences of the University of Texas Southwestern Medical Center. Dr. Tamminga serves as Member of Scientific Advisory Board at Karuna Therapeutics, Inc. She holds the McKenzie Foundation Chair in Psychiatry and the Communities Foundation of Texas, Inc. Chair in Brain Science. She serves as an ad hoc advisor to the NIMH Orphan Drug Program. She is the co-founder of the International Congress on Schizophrenia Research and continues to direct its activities. She served as an Advisor of PureTech Ventures. Previously, Dr. Tamminga was Professor of Psychiatry at the University of Maryland School of Medicine. Dr. Tamminga served as Chairman of Advisory Board of Avera Pharmaceuticals, Inc. She serves as Member of the Scientific Advisory Board of Karuna Pharmaceuticals and Nupathe, Inc. Dr. Tamminga serves as a Member of the Scientific & Clinical Advisory Board of ACADIA Pharmaceuticals Inc. She serves on the Scientific Board of NARSAD and the Scientific Advisory Board for the Stanley Foundation. She serves as Deputy Director of the Maryland Psychiatric Research Center, where she directed clinical and pre-clinical research in schizophrenia focused both on understanding disease mechanisms and on developing improved treatments. In 1978, Dr. Tamminga began her faculty appointment at the University of Maryland, MPRC, where she developed the inpatient research programs. She joined a schizophrenia research team at the NIMH for one year. Dr. Tamminga serves as the Chairman of Medical Advisory Board at Intra-Cellular Therapies, Inc. Dr. Tamminga is the recipient of numerous federal foundation and pharmaceutical-funded grants and is involved in a federally funded Mental Health Center at the MPRC. In 1998, Dr. Tamminga was invited to be a member of the NIDA Board of Scientific Counselors and was elected into the Institute of Medicine of the National Academy of Sciences. She has published over 300 papers and two books in the area of psychopharmacology, neuroscience, or schizophrenia. She has lectured nationally and internationally on treatments in schizophrenia and disease pathophysiology. Dr. Tamminga is the recipient of numerous awards in the field, most recently the University of Maryland Research Lecturer of the Year. She also received the Dean Award for Schizophrenia Research. Dr. Tamminga Graduated from Vanderbilt Medical School in 1971 and completed a Psychiatry Residency at the University of Chicago in 1975 and a Research Fellowship in Psychopharmacology in Chicago.
公司职务
- 公司名称Acadia Pharmaceuticals Inc.股票代码ACAD职务Member of the Scientific and Clinical Advisory Board共事同僚
- CECatherine E. Owen AdamsCEO & Director
- SRStephen Richard BiggarIndependent Chairman of the Board
- MCMark C. SchneyerExecutive VP & CFO
- JJJennifer J. RhodesExecutive VP, Chief Legal Officer & Secretary
- TAThomas Andrew GarnerExecutive VP & Chief Commercial Officer
- SCScott CenciSenior VP, Chief Information & Data Officer
- LALaura A. BregeIndependent Director
- HYHerbert Y. MeltzerMember of the Scientific and Clinical Advisory Board
